Filing identity and reporting period
The supplied filing is MEI Pharma, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2020 (the first quarter of fiscal 2021), filed November 10, 2020. This does not match the request metadata identifying Lite Strategy, Inc. and 2019 Q1; the summary below reflects the filing text provided.
Business context and key financial metrics
MEI Pharma is a clinical-stage oncology company. Its four clinical-stage drug candidates are zandelisib, voruciclib, ME-344 and pracinostat. The financial statements are unaudited; amounts below are in millions of dollars unless otherwise noted.
| Metric | Quarter ended Sep. 30, 2020 | Comparable 2019 quarter |
|---|---|---|
| Revenue | $3.834 | $1.157 |
| Cost of revenue | $0.509 | $0.688 |
| Research and development | $12.996 | $8.962 |
| General and administrative | $5.915 | $4.130 |
| Operating loss | $(15.586) | $(12.623) |
| Net loss | $(2.092) basic; $(15.316) diluted | $(2.994) |
| Net cash used in operating activities | $(9.111) | $(14.078) |
- At September 30, 2020, cash, cash equivalents and short-term investments totaled $176.135 million, including $165.179 million of short-term U.S. government securities. A $20.420 million foreign-tax withholding receivable was collected in October 2020.
- Total assets were $214.009 million; total liabilities were $131.681 million; stockholders’ equity was $82.328 million. The balance sheet reports no borrowings or other debt; operating lease liabilities totaled $8.674 million.
- Revenue was recognized over time under license and collaboration arrangements. The filing does not present a gross-margin measure.
Material changes versus the prior comparable period
- Revenue increased $2.677 million, chiefly from KKC agreement revenue, which rose to $3.569 million from $0.797 million. Helsinn revenue declined to $0.265 million from $0.360 million.
- Operating expenses increased $5.640 million. R&D growth reflected higher zandelisib trial activity and Phase 3 start-up costs, increased voruciclib manufacturing costs, and higher personnel and share-based compensation. G&A also increased, including personnel, professional services, legal and overhead costs.
- Operating loss widened by $2.963 million, while basic net loss narrowed. The difference was substantially affected by a $13.224 million noncash gain from the decline in fair value of the warrant liability. The diluted-loss calculation includes the warrant fair-value change and therefore reports a larger loss than basic net loss.
- Operating cash use decreased by $4.967 million, primarily due to working-capital changes. Financing provided $3.260 million, including $3.136 million of net proceeds from ATM share sales. Shares outstanding increased to 112.522 million from 73.655 million at September 30, 2019.
Outlook, management commentary, risks and unusual items
- Management expects operating losses and negative operating cash flows for the foreseeable future, with R&D spending expected to increase. It believes available resources, including the tax receivable subsequently collected, will fund operations into fiscal 2022 and beyond; the filing also states resources should cover obligations for at least 12 months from issuance.
- There is no formal financial forecast. TIDAL enrollment was projected to complete in calendar Q1 2021, subject to pandemic effects. Enrollment continued at a reduced rate, and management reported clinical-development timelines had been negatively affected by COVID-19.
- KKC paid a $100 million upfront amount in May 2020. The agreement provides for up to approximately $582.5 million in potential development, regulatory and commercialization milestones, plus tiered royalties on ex-U.S. sales. MEI and KKC share U.S. profits and costs 50/50; KKC is generally responsible for ex-U.S. development and commercialization costs. These potential payments are contingent, not assured revenue.
- MEI reported promising interim zandelisib Phase 1b response data, but results from early studies may not predict later outcomes. The Phase 2 pracinostat/azacitidine MDS study continued; Helsinn discontinued its Phase 3 AML study after an interim futility analysis and withdrew pracinostat’s AML breakthrough therapy designation.
- Two pracinostat-related putative lawsuits were pending: a securities class action and a derivative action. The company disputed the claims; outcomes and potential losses could not be predicted, and no loss was accrued.
- The San Diego office lease commenced in July 2020 and runs through March 2028; scheduled future minimum payments total $11.555 million before discounting. Potential milestone and royalty obligations under the Presage, S*Bio and CyDex arrangements were not accrued because the triggering events had not occurred.
Important facts for investors to verify
- Confirm the filing identity and period: the source is MEI Pharma’s September 2020 quarter, not Lite Strategy’s 2019 Q1.
- Review zandelisib trial progress, data maturity, safety, regulatory requirements and the effects of COVID-19 on enrollment and timing.
- Assess the pracinostat program following the discontinued AML Phase 3 study and Helsinn’s review of further development.
- Track cash burn, R&D growth, the collected $20.420 million tax receivable, and management’s funding-runway assumptions.
- Consider potential share dilution, including outstanding options and 16.062 million warrants exercisable at $2.54, as well as the fair-value-driven volatility in reported diluted loss.
- Monitor the pending litigation and the contingent milestones, royalties and lease commitments.